Lead Product(s) : 3-Aminopyrrolidine dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Aurigene
Deal Size : Undisclosed
Deal Type : Collaboration
Curis and Aurigene Announce Amendment of Collaboration
Details : Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer. Curis retains U.S., E.U., and rest of world rights to CA-170.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : 3-Aminopyrrolidine dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Aurigene
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?